Reference Guide for Bipolar Depression
SmartMobile(TM)Premiere Date: Tuesday, September 3, 2013
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, September 3, 2014
Note: Credit Is No Longer Available
|Michael E. Thase, MD
Professor of Psychiatry
Department of Psychiatry
Perelman School of Medicine at the University of Pennsylvania
Corporal Michael J. Crescenz Veterans Affairs Medical Center
In a United States-based study, the lifetime prevalence of bipolar disorder was 4.5%. Bipolar disorder (BPD) is associated with profound changes in quality of life and even premature death. BPD is among the leading causes of disability in the developed world among people 15 to 44 years of age.1
In the National Institute of Mental Health’s Collaborative Depression Study involving patients with bipolar I disorder who were followed for more than 12 years, patients were symptomatic almost 50% of the time. Depressive symptoms occurred about one-third of the time; manic symptoms occurred about 10% of the time. Mixed state symptoms occurred about 6% of the time. Low-level symptoms of depression are also associated with functional disability and subsequent depressive relapse. Bipolar depression is underrecognized and undertreated.2
This neuroscienceCME SmartMobile™ Reference Guide offers clinicians a unique opportunity to have salient data and reference materials available on their smartphones or mobile device at any time, right at the point of care, as a POC reference on bipolar depression.
- Merikangas KE, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543-552. PMID: 17485606.
- Frye MA, Yatham LN, Calabrese JR, et al. Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo controlled maintenance trials. J Clin Psychiatry. 2006;67(11):1721-1728. PMID: 17196051.
The goal of this activity is to provide clinicians with an easy–to-use, quick-reference guide to the differential diagnosis and treatment of bipolar depression.
At the end of this CE activity, participants should be able to:
- Screen for bipolar depression in patients who present with depressive symptomatology.
- Implement evidence- and measurement-based treatment plans for patients with diagnosis of bipolar depression.
Supported by an educational grant from Sunovion Pharmaceuticals Inc.
Physicians, physician assistants, and other health care professionals who do work with patients with bipolar depression.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Thase has disclosed that he has received research grants from Agency for Healthcare Research and Quality; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; National Institutes of Mental Health; and Otsuka America Pharmaceutical, Inc. He serves as a consultant for Alkermes, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Dey Pharma, L.P.; Eli Lilly and Company.; Forest Pharmaceuticals, Inc.; Gerson Lehrman Group, Inc.; Guidepoint Global; H. Lundbeck A/S; MedAvante, Inc.; Merck & Co., Inc.; Neuronetics; Novartis Corporation; Otsuka America Pharmaceutical, Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Pamlab, LLC; Pfizer Inc. (formerly Wyeth Ayerst Pharmaceuticals; Schering-Plough (formerly Organon, Inc.); Shire US Inc..; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; and Transcept Pharmaceuticals , Inc. He has equity holdings in MedAvante, Inc. and received royalties from American Psychiatric Foundation; Guilford Publications; Herald Publishing House; and W.W. Norton & Company, Inc. His spouse is employed as a Group Scientific Director for Embryon (formerly Advogent), which does business with BMS and Pfizer Inc./Wyeth.
Robert Kennedy (planning committee) has no disclosures to report.
Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Sunovion Pharmaceuticals, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).